Resistance to activated protein C (APC) is a major risk factor for venous thrombosis that is caused by a point-mutation in the gene of blood coagulation factor V [1, 2] . This mutation (FV Leiden) renders the FV molecule less susceptible to inactivation by APC, and is seen in 20-40% of patients with VTE [3] . It is thus the most common hereditary risk factor for VTE among Caucasians. An increased resistance to APC determined with a thrombin generation-based test in patients with the FV Leiden mutation has shown a good correlation between APC sensitivity ratios (APCsr) and the risk of venous thrombosis in carriers of FV Leiden [4, 5] . D-dimer measurements have also been used for predicting recurrent VTE and measured after withdrawal of oral anticoagulant treatment D-dimer had some predictive value with regard to reccurrence, but the overall discriminative power was quite poor (AUC 0.59 ± 0.03) [6] [7] [8] [9] [10] . The risks of DVT with the joint presence of high Ddimer and FV Leiden was increased 12.4 -fold and were thus supra-additive in a prospective case-control study [11] . There is a need for more specific laboratory markers that can be used to predict an elevated risk for recurrent VTE, especially in patients without hereditary risk factors for thrombophilia.
A new sensitive sandwich immunofluorimetric assay for measurements of the complex between APC and the protein C inhibitor (APC-PCI complex) has been devised [12, 13] . This method employs a monoclonal antibody that is specific for the loop-inserted form of the inhibitor, i.e. PCI that is in complex with APC. Un-complexed native PCI, which exists in a 10 4 -fold molar excess over the APC-PCI complex has no affinity for the antibody.
As a so-called reporter antibody a monoclonal antibody against protein C is used. Due to the activation of protein C by thrombin bound to thrombomodulin, and the subsequent inactivation of APC by PCI, the concentration of the APC-PCI complex is a sensitive indicator of the degree of activation of blood coagulation. Increased levels of APC-PCI have been observed in hyper-coagulation states both affecting the venous and arterial systems such as deep vein thrombosis (DVT), pulmonary embolism, disseminated intravascular coagulation and myocardial infarction (MI) [14] [15] [16] . Measured with our method in patients with VTE and MI, ROC-analysis demonstrated an equal or better discriminative capacity than other markers of hypercoagulability such as F1+2, TAT, SFM and D-dimer [17] [18] . The aim of the present study is to find out if there is a difference in APC-PCI concentration indicating different degrees of thrombin generation between carriers and non-carriers of the FV Leiden mutation in patients with a previous history of VTE.
Venous blood was drawn after information and written consent. It was collected in 5 mL vacuum tubes (Stabilyte, Biopool, Umeå, Sweden) containing citrate with a low pH, which precludes in vitro formation of the APC-PCI complex [19] . The APC-PCI complex concentration was measured using the previously described DELFIA assay, which has a The capacity of the methods to discriminate VTE-patients with FV-Leiden from VTE-patients without, was compared in a ROC-analysis (receiver operating characteristics; shown to be increased 12.4 -fold and were thus supra-additive in a prospective case-control study [11] . Our study suggests that the APC-PCI complex concentration, which in contrast to D-dimer is a well defined analyte, could be a marker of an increased risk for future VTE.
However, clinical intervention studies need to be performed to study if withdrawal of oral anticoagulant treatment can be based on APC-PCI complex determinations. Legend to figure   Fig. 1 Box-plots representing APC-PCI concentrations (dark boxes) in normals (n=80) [19] and in patients with a previous VTE episode, with the FV Leiden mutation or without any 
